Joint (NASDAQ:JYNT) Earns Buy Rating from Analysts at B. Riley
B. Riley initiated coverage on shares of Joint (NASDAQ:JYNT) in a research report sent to investors on Thursday morning, 24/7 WallStreet reports. The brokerage issued a buy rating and a $23.00 target price on the stock.
JYNT has been the topic of a number of other research reports. Roth Capital lifted their target price on shares of Joint from $16.00 to $23.00 and gave the company a buy rating in a research note on Monday, June 3rd. DA Davidson set a $21.00 target price on shares of Joint and gave the company a buy rating in a research note on Thursday, May 23rd. Lake Street Capital lifted their target price on shares of Joint to $20.00 and gave the company a buy rating in a research note on Friday, March 8th. Zacks Investment Research lowered shares of Joint from a hold rating to a sell rating in a research note on Wednesday, March 13th. Finally, ValuEngine raised shares of Joint from a buy rating to a strong-buy rating in a research note on Wednesday, February 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $21.17.
Shares of JYNT opened at $17.35 on Thursday. The stock has a market cap of $239.17 million, a PE ratio of 123.93, a P/E/G ratio of 7.89 and a beta of 0.93. The company has a debt-to-equity ratio of 4.38, a quick ratio of 1.00 and a current ratio of 1.00. Joint has a 1-year low of $6.51 and a 1-year high of $19.81.
In related news, Director Ronald V. Davella sold 10,190 shares of Joint stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $16.46, for a total transaction of $167,727.40. Following the completion of the transaction, the director now directly owns 15,457 shares of the company’s stock, valued at approximately $254,422.22. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director James H. Amos, Jr. purchased 4,000 shares of the stock in a transaction that occurred on Wednesday, June 5th. The shares were acquired at an average cost of $16.08 per share, with a total value of $64,320.00. Following the completion of the transaction, the director now owns 80,497 shares in the company, valued at $1,294,391.76. The disclosure for this purchase can be found here. Company insiders own 6.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC lifted its position in Joint by 10.1% during the 4th quarter. Nantahala Capital Management LLC now owns 1,128,693 shares of the company’s stock valued at $9,391,000 after acquiring an additional 103,972 shares during the period. Vanguard Group Inc. raised its holdings in Joint by 7.0% in the third quarter. Vanguard Group Inc. now owns 276,974 shares of the company’s stock worth $2,368,000 after buying an additional 18,099 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Joint by 13.9% in the first quarter. Acadian Asset Management LLC now owns 217,266 shares of the company’s stock worth $3,422,000 after buying an additional 26,564 shares during the last quarter. Granite Investment Partners LLC raised its holdings in Joint by 87.7% in the first quarter. Granite Investment Partners LLC now owns 149,203 shares of the company’s stock worth $2,350,000 after buying an additional 69,711 shares during the last quarter. Finally, Spark Investment Management LLC raised its holdings in Joint by 43.9% in the first quarter. Spark Investment Management LLC now owns 69,928 shares of the company’s stock worth $1,101,000 after buying an additional 21,328 shares during the last quarter. 51.97% of the stock is owned by institutional investors.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.